OncoMatch/Clinical Trials/NCT03051464
No Surgery Trial / Two Dose-escalation Strategies
Is NCT03051464 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies non-drug interventions for stage ii rectal cancer.
A randomized study of 131 patients. Patients with a clinical T2-3 N0 rectal cancer will be randomized to two arms (arm A: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy compared to arm B: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions).
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Prior therapy
Cannot have received: pelvic radiation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UT Southwestern Medical Center · Dallas, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify